Health-related quality of life and colorectal cancer-specific symptoms in patients with chemotherapy-refractory metastatic disease treated with panitumumab by Odom, Dawn et al.
ORIGINAL ARTICLE
Health-related quality of life and colorectal cancer-specific
symptoms in patients with chemotherapy-refractory
metastatic disease treated with panitumumab
Dawn Odom & Beth Barber & Lee Bennett &
Marc Peeters & Zhongyun Zhao & James Kaye &
Michael Wolf & Jeffrey Wiezorek
Accepted: 3 December 2010 /Published online: 29 December 2010
# The Author(s) 2010. This article is published with open access at Springerlink.com
Abstract
Purpose Panitumumab monotherapy is approved for
chemotherapy-refractory wild-type KRAS metastatic colorec-
tal cancer (mCRC). Patient-reported outcomes—although
important in the palliative setting—have not been reported in
this patient population.
Methods In a phase 3 trial (n=463), patients with
chemotherapy-refractory mCRC were randomized 1:1 to
panitumumab plus best supportive care (BSC) or BSC
alone. Patient-reported outcomes were assessed using the
NCCN/FACT CRC Symptom Index (FCSI) and EQ-5D
Index. KRAS tumor status was analyzed in a prospectively
defined, retrospective analysis. Average difference in
change from baseline between treatment groups was
evaluated using linear mixed and pattern-mixture models.
Results KRAS tumor status and post-baseline patient-
reported outcomes were available for 363 patients. Linear
mixed models indicated significant differences in the FCSI
score (difference in least-squares [LS] adjusted means [95%
CI]; 5.62 [2.38, 8.86]) and the EQ-5D Index (difference in
LS adjusted means [95% CI]; 0.22 [0.12, 0.32]) favoring
panitumumab over BSC in patients with wild-type KRAS
mCRC. By pattern-mixture analysis, the advantage of
panitumumab over BSC was more pronounced in those
patients with wild-type KRAS mCRC who did not drop out
of the study early. In patients with mutant KRAS mCRC, no
differences were observed between groups.
Conclusions Panitumumab-treated patients with wild-type
KRAS mCRC maintained better control of CRC symptoms
and quality of life compared with BSC alone, extending our
understanding of the benefits of panitumumab treatment
beyond improvements in progression-free survival.
Keywords Panitumumab.KRAS.Colorectal cancer.
Symptoms.HRQoL
Introduction
Colorectal cancer (CRC) is a major health concern,
representing the third most commonly diagnosed cancer
worldwide and the second leading cause of cancer
mortality in the developed world [1, 2]. Following
significant improvements in the treatment of CRC as a
result of advances in systemic chemotherapy [3], use of
agents targeting the vascular endothelial growth factor
and epidermal growth factor receptor (EGFR) now also
have an established role in patients with metastatic disease
[4–6].
Panitumumab is a fully human monoclonal antibody
directed against the EGFR. Its clinical efficacy in metastatic
CRC (mCRC) was confirmed in an open-label, phase 3
trial, in which patients receiving panitumumab plus best
supportive care (BSC) had significantly improved
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DOI 10.1007/s00384-010-1112-5progression-free survival (PFS) compared with those
receiving BSC alone (hazard ratio [HR] 0.54; 95%
confidence interval [CI], 0.44 to 0.66) [6] in patients with
chemotherapy-refractory mCRC. Mutations in KRAS—a
gene encoding a GTPase that mediates downstream
intracellular EGFR signaling—are found in approximately
35–45% of CRC tumors [7] and have been associated with
a lack of response to EGFR inhibitors when used for
mCRC [8]. Evaluation of the predictive role of KRAS
mutational status in the response to panitumumab in this
phase 3 monotherapy study identified that its beneficial
effect was restricted to patients whose tumors had wild-type
KRAS. In patients with wild-type KRAS mCRC, panitumu-
mab plus BSC was associated with a statistically significant
improvement in median PFS compared with BSC alone
(HR, 0.45; 95% CI, 0.34–0.59 [9]). In mCRC, the clinical
use of panitumumab (like cetuximab) is therefore now
restricted to patients with wild-type KRAS tumors. Despite
recent advances in the treatment of mCRC provided by
targeted agents, most patients will eventually die of the
disease. The goal of therapy in this setting is, therefore, to
delay disease progression, control symptoms, and maintain
health-related quality of life (HRQoL) for as long as
possible [10, 11]. As such, patient-reported outcomes are
particularly important to patients with metastatic disease,
and the potential for benefit related to these outcomes is a
key consideration in the choice of therapy [12].
During the phase 3 trial of panitumumab monotherapy,
HRQoL and CRC symptom data were collected. Patient-
reported outcomes from the trial were briefly reported in the
primary efficacy paper but only for the overall patient
population and not by KRAS tumor status [6] (online
appendix only). Since panitumumab is only indicated for
patients with wild-type KRAS tumor status, the available
patient-reported outcomes data do not, therefore, reflect the
findings for the population for whom treatment with
panitumumab is appropriate. In addition, there was a large
amount of missing patient-reported outcome data that was
unlikely to be missing at random: as expected for patients
with advanced refractory disease, more than 50% of
patients in the BSC alone arm and KRAS mutant patients
in panitumumab plus BSC arm had progressed by week
8[ 6], and thus missing data are likely to have been related
to declining health. The last-observation-carried-forward
(LOCF) method used in the previous overall population
analysis of HRQoL data is therefore a less-than-optimal
approach to evaluate the true impact of panitumumab on
patient-reported outcomes.
Using data from this phase 3 trial, we therefore sought to
evaluate the impact of panitumumab on patient-reported
outcomes according to KRAS tumor status and including
statistical analyses aimed at properly accounting for the
missing data.
Patients and methods
Patients and study design
The patient population and design for this phase 3, open-
label, randomized, controlled trial (n=463) have been
described elsewhere [6, 9]. Briefly, patients with EGFR-
detectable mCRC and documented evidence of disease
progression after failure of fluoropyrimidines and prespeci-
fied exposure to oxaliplatin and irinotecan were randomly
assigned to receive panitumumab 6 mg/kg plus BSC every
2 weeks or BSC alone. The primary endpoint of the study
was PFS, with progression assessed by central radiologic
review at specified time points from weeks 8 to 48, then
every 3 months thereafter. The KRAS tumor status was
evaluated in a prospectively defined, retrospective analysis
of formalin-fixed paraffin-embedded tumor sections in a
blinded fashion, using a validated KRAS mutation kit [9].
The study protocol was approved by the ethics board at
each research center, and patients provided written in-
formed consent, including that for research into the
paraffin-embedded tumor samples provided at baseline.
An independent clinical research organization (working on
behalf of the study sponsor) monitored study centers in
Central and Eastern Europe, and representatives of the
study sponsor monitored study centers in the rest of world.
Monitors were responsible for reviewing adherence to the
protocol, compliance with Good Clinical Practice, and the
completeness, accuracy, and consistency of the data.
Patient-reported outcome instruments and data collection
Colorectal cancer symptoms were assessed using the
National Comprehensive Cancer Network (NCCN) Func-
tional Assessment of Cancer Therapy, Colorectal Symptom
Index (FCSI). The FCSI is a validated, nine-item question-
naire that addresses the most important symptoms associ-
ated with CRC, including fatigue, pain, weight loss,
diarrhea, nausea, stomach swelling/cramps and appetite,
and more general aspects of HRQoL such as ability to
enjoy life and contentedness in quality of life (QoL) [13].
Patients responded to each item of this questionnaire using
a five-point Likert-type scale ranging from 0 (not at all) to 4
(very much). Raw FCSI scores, which range from 0 to 36,
were converted to total scores ranging from 0 (severely
symptomatic in all symptoms assessed) to 100 (symptom-
free for all symptoms assessed) using published scoring
methodology [13]. The minimal clinically important differ-
ence (MCID) was defined as a change in score of 3 points
or more [14]. This instrument was administered at baseline
and then every 2 weeks until disease progression.
Overall HRQoL was measured at baseline and monthly
until disease progression using the EuroQol 5-Dimensions
174 Int J Colorectal Dis (2011) 26:173–181(EQ-5D) Index. The EQ-5D Index is a generic preference-
based measure of overall QoL, as assessed across five
dimensions: mobility, self-care, usual activity, pain or
discomfort, and anxiety or depression. Each dimension
has three possible responses (no problems, moderate
problems, or extreme problems). The EQ-5D Index score
is calculated by combining scores from the five dimensions
using population-based preference weights and ranges from
−0.594 to 1 [15]. The MCID for the EQ-5D Index in
patients with mCRC has been estimated as a change in
score of 0.08 points or more [16].
Statistical analysis
The primary objective of this analysis was to estimate the
average difference in effect of panitumumab plus BSC
treatment compared with BSC alone on the FCSI and
EQ-5D Index, both overall and for the wild-type and
mutant KRAS subgroups. KRAS tumor status was ascer-
tained in 92% of patients enrolled in the phase 3 trial [9].
The analysis set was defined as all patients in the intent-to-
treat population (all subjects who gave consent and were
randomized) who had at least one post-baseline FCSI or
EQ-5D Index assessment and an assessed KRAS status
(“KRAS patient-reported outcome (PRO) analysis set”).
Only outcomes obtained through week 17 of the study were
used due to small sample sizes after week 17. Change in
score from baseline was analyzed over time using linear
mixed models for repeated measures [17]. The models
included explanatory variables for study treatment arm,
study week, and the interaction between treatment arm and
study week. Each repeated measures model also included
adjustments for baseline outcome score, baseline collection
medium, baseline Eastern Cooperative Oncology Group
(ECOG) performance status, and geographic region.
Treatment-specific estimates of the average change in each
outcome score from baseline, along with 95% CI, were
calculated for the overall cohort and for each KRAS
subgroup using least-squares mean (LSM) differences.
To evaluate the effect of study attrition on the estimates of
treatment differences, a sensitivity analysis was performed
using pattern-mixture models [18, 19], which are linear
models that incorporate information about missing data. For
each endpoint, patients were first categorized according to the
last week for which outcome data were collected up to week
17. These categories were then collapsed into larger groups of
patients representing two general patterns of missing response
data: those who dropped out of the study early (“early
dropout”) and those who either dropped out later or
completed all assessments up to week 17 (“late dropout/
completer”). For the EQ-5D Index, we defined the “early
dropout” group as those who dropped out on or before week
9a n dt h e“late dropout/completer” group as those who
dropped out after week 9 or did not drop out of the study
early. To account for the more frequent assessments, FCSI
“early dropout” group was defined as those who dropped out
before week 9 and the “late dropout/completer” group as
those who dropped out on or after week 9 or did not drop out.
Dropout status was incorporated into pattern-mixture
models of change in score from baseline for each outcome.
These models included fixed effects for treatment arm, study
week, dropout pattern group, and interactions between these
effects. The model included random effects to account for
variability in outcome scores at baseline and over time among
patients. Within each dropout group, treatment-specific LSM
estimates of average change in each outcome score from
baseline, along with 95% CI, were calculated for each KRAS
subgroup and overall. All statistical analyses were performed
using SAS for Linux, Version 9.1 (SAS Institute).
Results
Of the 463 patients randomly assigned to treatment in the
main study, information on tumor KRAS status together
with post-baseline patient-reported outcome data was
available for 363 patients (KRAS PRO analysis set, n=188
panitumumab plus BSC; n=175 BSC alone), representing
78% of the overall study population. Baseline character-
istics were generally well-balanced across treatment groups
and were similar to those reported in the overall patient
population [6], with the exception of a slightly higher
percentage of better performing patients (ECOG=0) in the
panitumumab plus BSC compared with the BSC alone
treatment group, overall and for each KRAS group (Table 1).
Patient-reported CRC symptoms and HRQoL
Table 2 presents the number of patients completing FCSI
questionnaires for each week until week 17. In line with
previous reports [20, 21], the amount of missing data was
substantial, particularly in the later weeks, although patients
with wild-type KRAS mCRC receiving panitumumab plus
BSC had a higher percentage of available data for each
post-baseline week compared with those receiving BSC
alone. Similar results were seen for the EQ-5D Index (data
not shown).
Change in scores from baseline—linear mixed model
According to the repeated-measures model of change from
baseline score, there was less deterioration in the FCSI
score and EQ-5D Index in the panitumumab plus BSC
group compared with the BSC alone group, both overall
and for the subgroup of patients with wild-type KRAS
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between treatment groups across all weeks favored pan-
itumumab by 3.60 (95% CI, 0.90 to 6.30) overall and 5.62
(95% CI, 2.38 to 8.86) for patients with wild-type KRAS
mCRC (Fig. 1a). The results of EQ-5D Index also favored
panitumumab, with an average LSM difference between
treatment groups across all weeks of 0.17 (95% CI, 0.09 to
0.25) overall and 0.22 (95% CI, 0.12 to 0.32) for patients
Table 1 Baseline characteristics of randomized patients with information on tumor KRAS status plus post-baseline data on FCSI score and
EQ-5D Index (KRAS PRO analysis set)
Panitumumab plus BSC BSC alone
Overall
(n=188), n (%)
Wild-type KRAS
(n=112), n (%)
Mutant KRAS
(n=76), n (%)
Overall
(n=175), n (%)
Wild-type KRAS
(n=96), n (%)
Mutant KRAS
(n=79), n (%)
Sex
Men 123 (65) 79 (701) 44 (58) 113 (65) 62 (645) 51 (65)
Women 65 (35) 33 (29) 32 (42) 62 (35) 34 (35) 28 (35)
Race/ethnicity
White 187 (99) 111 (99) 76 (100) 171 (98) 95 (99) 76 (96)
Other 1 (1) 1(1) 0 (0) 4 (2) 1 (1) 3 (4)
Age, years
Mean (SD) 61 (10) 62 (10) 60 (11) 62 (10) 62 (10) 61 (11)
Primary diagnosis
Colon cancer 126 (67) 78 (70) 48 (63) 117 (67) 68 (71) 49 (62)
Rectal cancer 62 (33) 34 (30) 28 (37) 58 (33) 28 (29) 30 (38)
ECOG
0 91 (48) 52 (46) 39 (51) 62 (35) 35 (36) 27 (34)
1 76 (40) 50 (45) 26 (34) 91 (52) 51 (53) 40 (51)
2 21 (11) 10 (9) 11 (14) 22 (13) 10 (10) 12 (15)
Time since primary diagnosis, months
Mean (SD) 31 (22) 33 (25) 27 (17) 32 (21) 31 (20) 34 (21)
Time since metastatic disease, months
Mean (SD) 21 (10) 22 (10) 20 (10) 22 (11) 24 (13) 19 (8)
Baseline EQ-5D Index
Mean (SD) 0.72 (0.24) 0.73 (0.24) 0.71 (0.25) 0.68 (0.25) 0.68 (0.23) 0.68 (0.26)
Baseline FSCI score
Mean (SD) 72.27 (13.69) 73.21 (13.05) 70.94 (14.55) 71.84 (14.28) 71.78 (13.48) 71.91 (15.28)
FCSI Functional Assessment of Cancer Therapy, Colorectal Symptom Index, EQ-5D Index EuroQol 5-Dimensions Index, PRO patient-reported
outcomes, BSC best supportive care, SD standard deviation
Table 2 Number of patients completing the FCSI (KRAS PRO analysis set)
Panitumumab plus BSC BSC alone
Overall Wild-type KRAS Mutant KRAS Overall Wild-type KRAS Mutant KRAS
Number of patients 188 112 76 175 96 79
Week 1 (baseline) 177 104 73 172 94 78
Week 3 167 102 65 139 78 61
Week 5 170 103 67 123 78 45
Week 7 152 96 56 91 62 29
Week 9 100 70 30 47 28 19
Week 13 80 63 17 13 9 4
Week 17 62 56 6 7 6 1
FCSI Functional Assessment of Cancer Therapy, Colorectal Symptom Index, PRO patient-reported outcomes, BSC best supportive care
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with wild-type KRAS mCRC, in particular, the differences
between treatment groups substantially exceeded each
instrument’s MCID. Most notably, the difference between
treatments in EQ-5D Index change was 2.75 times higher
than the MCID in patients with wild-type KRAS mCRC. As
expected, analysis of the mutant KRAS group did not show
any significant differences in change from baseline FCSI
score or EQ-5D Index between treatments (FCSI score:
average LSM difference between treatment groups across
all weeks of −1.41 [95% CI, −6.41 to 3.59]; EQ-5D Index:
average LSM difference between treatment groups across
all weeks of 0.08 [95% CI, −0.04 to 0.19]).
Pattern-mixture model (sensitivity analysis)
For each outcome, missing data were categorized into early
and late dropout patterns, regardless of treatment group or
KRAS status. Based on a simple cross-sectional average,
Fig. 2 illustrates that there was a clear difference in the
FCSI score of the early and late dropout groups at each time
point. Similar results were seen for the EQ-5D Index (data
not shown).
For both the FCSI score and EQ-5D Index, the
panitumumab plus BSC group had a significantly higher
proportion of patients in the late dropout group than in the
early dropout group, whereas the BSC alone group had a
significantly higher proportion of patients in the early
dropout group (P<0.001; Table 3). Together, these data
indicate that the dropout pattern was informative about the
treatment group as well as the patient-reported outcomes,
and thus the missing data were considered to be
non-random, and treatment effects were evaluated separate-
ly for those patients who did and those who did not drop
out early.
Table 4 displays the results of the pattern-mixture
analyses modeling average differences in change from
baseline score for the FCSI and EQ-5D Index. For late
dropout patients with wild-type KRAS mCRC, those
receiving panitumumab experienced an initial increase in
EQ-5D Index and FCSI scores that was not observed in
patients receiving BSC alone. In this group, the LSM
difference between groups was statistically significant in
favor of panitumumab with differences in both instruments
exceeding the relevant MCIDs, consistent with the findings
from the repeated-measures model (Table 4). On the EQ-5D
index, differences between treatment groups were four
times higher than the MCID and substantially exceeded the
panitumumab advantage seen in the repeated-measures
model. These treatment advantages were not evident for
patients in the early dropout pattern group with wild-type
KRAS mCRC (Table 4). Similar to the linear model, there
were also no significant differences between the treatments
in patients with mutant KRAS mCRC (Table 4).
Based on the FCSI assessment of symptoms among
patients with wild-type KRAS mCRC who stayed on study,
Fig. 2 Unadjusted average change from baseline in FCSI score by
week of assessment and dropout pattern (KRAS PRO analysis set).
FSCI Functional Assessment of Cancer Therapy, Colorectal Symptom
Index
Fig. 1 a Least-squares mean differences in the change from baseline
in the FCSI scores between panitumumab plus BSC and BSC alone
for patients with wild-type KRAS mCRC by analysis week, linear
mixed models. Note: This model includes data only through week 13.
Inclusion of week 17 data, which are missing for more than 80% of
the analysis population, caused model instability to the extent that
treatment effects could not be estimated. b Least-squares mean
differences in the change from baseline in the EQ-5D Index between
panitumumab plus BSC and BSC alone for patients with wild-type
KRAS mCRC by analysis week (KRAS PRO analysis set), linear
mixed models. FSCI Functional Assessment of Cancer Therapy,
Colorectal Symptom Index; BSC best supportive care; mCRC
metastatic colorectal cancer; EQ-5D EuroQol 5-Dimensions Index
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be consistent across all weeks of the study (Fig. 3a),
whereas the treatment advantage favoring panitumumab on
the EQ-5D Index became larger as time increased, with the
greatest advantage over BSC alone seen at week 17
(Fig. 3b).
Discussion
Patient-reported outcomes such as cancer-related symptom-
atology and QoL are increasingly being recognized as
important aspects of palliative care in the advanced cancer
setting, providing important information to help make
treatment decisions [12]. In this analysis, patients treated
with panitumumab showed significantly better control of
CRC symptoms and maintenance of HRQoL compared
with those who received BSC alone: this benefit was most
evident among the subgroup of patients with wild-type
KRAS mCRC and was not seen in patients with mutant
KRAS mCRC, or in those dropping out of the study early.
This therefore illustrates, for the first time, the beneficial
effects of panitumumab on HRQoL in patients with wild-
type KRAS mCRC, the population for whom panitumumab
treatment is indicated in clinical practice. Indeed, in those
patients with wild-type KRAS mCRC treated with panitu-
mumab who did not drop out of the study early, a decrease
in CRC-related symptoms and an increase in HRQoL was
observed by week 3 of the study. This is consistent with the
finding that the beneficial effects of panitumumab on PFS
are limited to patients with wild-type KRAS mCRC [9] and
with previous analyses indicating that a lack of disease
progression at week 8 provided by panitumumab was
associated with better HRQoL and symptom control [20].
For HRQoL and CRC symptoms, the benefits of panitu-
mumab compared with BSC alone in patients with wild-
type KRAS mCRC exceeded the established MCID levels,
indicating that statistical differences were also clinically
relevant. To our knowledge, our analyses are the first to
illustrate the beneficial effects of an EGFR inhibitor on
CRC-specific symptomatology, which is particularly im-
portant given that treatment of patients with mCRC is
primarily given with palliative intent [10, 11].
The HRQoL of patients with advanced CRC treated with
the EGFR inhibitor cetuximab, overall and by KRAS status,
has also been published recently [22]. The findings were
generally consistent with ours in that HRQoL benefits of
cetuximab were observed and were most apparent in the
subgroup of patients with wild-type KRAS mCRC. How-
ever, the results cannot be more closely compared, as the
Table 3 Summary of dropout pattern by treatment (KRAS PRO analysis set)
Instrument/pattern Panitumumab plus BSC (n=188), n (%) BSC (n=175), n (%) P value
FCSI <0.001
Early dropout 75 (42) 109 (68)
Late dropout/completer 101 (57) 49 (31)
EQ-5D Index <0.001
Early dropout 65 (38) 99 (68)
Late dropout/completer 105 (62) 47 (32)
Patients with missing data for all post-baseline assessments were excluded from the analysis. P values are based on the Pearson chi-square test
PRO patient-reported outcomes, BSC best supportive care, FCSI Functional Assessment of Cancer Therapy, Colorectal Symptom Index,
EQ-5D Index EuroQol 5-Dimensions Index
Table 4 Least-squares mean differences (95% CI) in the change from baseline in the EQ-5D Index score and FCSI scores between panitumumab
plus BSC vs BSC alone: overall and by tumor KRAS status, using pattern-mixture models (KRAS PRO analysis set)
EQ-5D Index FCSI
Dropout pattern Overall Wild-type KRAS Mutant KRAS Overall Wild-type KRAS Mutant KRAS
Early dropout −0.08 (-0.21, 0.05) −0.19 (-0.38, 0.01) −0.02 (-0.19, 0.15) 0.53 (-3.15, 4.20) −2.21 (-7.16, 2.75) 4.27 (-1.33, 9.88)
Late dropout/
completer
0.26
a,* (0.16, 0.37) 0.32
a,* (0.18, 0.45) 0.13 (-0.03, 0.29) 3.63 (-0.05, 7.31) 5.75*
,a (1.45, 10.04) −0.66 (-7.27, 5.95)
CI, confidence interval EQ-5D Index EuroQol 5-Dimensions Index; FCSI Functional Assessment of Cancer Therapy, Colorectal Symptom Index;
BSC best supportive care; PRO patient-reported outcomes
aExceeds minimum clinically important difference (EQ-5D Index=0.08 points [16]; FCSI=3 points [14])
*P≤0.05
178 Int J Colorectal Dis (2011) 26:173–181cetuximab analysis used data from the EORTC QLQ-C30,
which includes cancer-related (but not CRC-specific)
symptoms [22], whereas we chose to evaluate HRQoL
and CRC-specific symptoms separately. In addition, in the
study of Au et al. [22], HRQoL data continued to be
collected after disease progression. Inclusion of such data
was not possible in our analysis since the study was
designed to allow cross-over from BSC to panitumumab at
this point [6].
Taken together with those of the cetuximab analyses
[22], these HRQoL results may, however, contribute to a
more accurate evaluation of the balance between the
positive effects of EGFR inhibitors and the side effects
associated with their use, such as skin toxicity, which are
generally perceived to have a detrimental effect on HRQoL
[23]. In the main study population of the phase 3 trial, skin
toxicity occurred in 90% of patients in the panitumumab
group compared with 9% of patients in the BSC group [6]
and was more likely to develop in patients remaining on the
study because of treatment benefit [21]. Despite the
association of skin toxicity with prolonged treatment, the
benefits of panitumumab in terms of HRQoL and symp-
tomatology were most apparent in the group of patients
with wild-type KRAS mCRC who did not drop out of the
study early in our analysis. Indeed, more severe skin
toxicity in association with panitumumab has been associ-
ated with higher rather than lower HRQoL scores [21].
Similar findings in relation to skin toxicity and HRQoL
have also been observed with cetuximab and have been
suggested to reflect an understanding by patients that skin
rash is indicative of a response to therapy, which helps them
cope with this side effect [24]. As noted by Au et al. [22],
the presence of skin rash also introduces the potential for
bias in the HRQoL results, since those patients experienc-
ing it may have been more likely to report improvements if
they were aware that the rash was a known predictor of
benefit. However, this suggestion would be at odds with the
fact that the benefits of panitumumab in terms of HRQoL
were most prominent in patients with wild-type KRAS
mCRC who were more likely to experience objective tumor
control than those with KRAS mutant tumors, and these
HRQoL benefits were not seen in patients with mutant
KRAS mCRC despite the fact that the vast majority of this
subpopulation also developed skin rash.
Our results differ from the original protocol-specified
analysis of HRQoL and CRC symptom control, which did
not take into account KRAS mutation status and which used
the LOCF imputation method. This showed a numerical
trend favoring panitumumab that did not reach statistical
significance [6]. The differences in outcome highlight both
the importance of tumor KRAS status and the need to
properly account for missing HRQoL data in trials of late-
stage disease in which the reasons for missing observations
are often related to deterioration in a patient’s clinical status
and so, cannot be classified as missing at random [25]. For
a patient who has rapid disease progression and drops out
of the study early, LOCF analysis is likely to impute values
indicating better health than the true value, potentially
biasing the comparison in favor of less effective or less
well-tolerated treatment. An advantage to using the
repeated-measures models (as in our analysis) is that
imputation is not required. Pattern-mixture models provide
even greater flexibility since the methodology provides a
way to incorporate information about patient dropout into
the longitudinal model.
Our sensitivity analyses showed that there were signif-
icantly fewer early dropouts for both the HRQoL and CRC
symptom scales among the group receiving panitumumab
than among the group receiving BSC alone. This dispro-
portionate percentage of data by treatment group likely
resulted from the higher rate of discontinuation due to death
or disease progression in the BSC only treatment arm [6],
and it was important to account for these non-random
Fig. 3 a Least-squares mean differences in the change from baseline
in the FCSI scores between panitumumab plus BSC and BSC alone
for patients with wild-type KRAS mCRC in the late dropout group by
analysis week, pattern-mixture model. b Least-squares mean differ-
ences in the change from baseline in the EQ-5D Index score between
panitumumab plus BSC and BSC alone for patients with wild-type
KRAS mCRC in the late dropout group by analysis week, pattern-
mixture model. FSCI Functional Assessment of Cancer Therapy,
Colorectal Symptom Index, BSC best supportive care, mCRC
metastatic colorectal cancer, EQ-5D EuroQol 5-Dimensions Index
Int J Colorectal Dis (2011) 26:173–181 179missing data. Of note is that similar findings regarding
disproportionatemissing data wereobservedin the cetuximab
analysis of Au et al. [22] (although not to the same extent as
there was an attempt to collect HRQoL data beyond disease
progression), and similar approaches to account for missing
data were included in their sensitivity analysis [22].
There are several possible explanations for the apparent
lack of effect of panitumumab, in those patients (even with
wild-type KRAS mCRC) who dropped out of the study
early. Patients treated with panitumumab plus BSC who left
the study early due to tolerability concerns or other reasons
unrelated to disease progression may not have received
enough treatment to yield an improvement in HRQoL or
CRC symptoms. Alternatively, the treatment may not have
been effective among a subgroup of patients, leading to
relatively rapid progression of disease and early dropout.
A potential limitation of this study is that KRAS mutation
status was determined retrospectively and therefore was not
a stratification factor in the randomization. However, 92%
of patients randomized had KRAS status available, and
patients with KRAS mutations were well distributed
between the two treatment groups. Although the post hoc
nature of our exploratory analysis by KRAS status is a
theoretical limitation, the comparison of baseline demo-
graphics suggests that, within the KRAS subgroups, patient
characteristics were similar between the two treatment
arms. Another potential limitation is the imperfect sensitiv-
ity and specificity of patient-reported outcome measures.
However, our analysis used validated instruments, and our
findings are supported by their consistency with the results
of the primary study endpoint, PFS.
In conclusion, our analyses illustrate the clinically signifi-
cant beneficial effects of panitumumab in terms of CRC-
specific symptom control and maintenance of HRQoL in
patients with wild-type KRAS mCRC, and these findings
extend our understanding of the benefits of panitumumab
treatment beyond improvements in PFS. These benefits were
apparent despite skin toxicity associated with panitumumab
treatment and provide important additional information for
both patients and physicians when making treatment decisions
for mCRC, particularly when the treatment intent is palliative.
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